Pulse Explorar nav.journalClub Debates Tendências Pesquisadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Início Explorar nav.journalClub Tendências

⌘+K

Design, Rationale, and Methods of the INITIATE-HFrEF Trial | Synapse

February 8, 2026JACC Advances0 citationsOpen Access

View Full Paper

Design, Rationale, and Methods of the INITIATE-HFrEF Trial

JFJoão Pedro FerreiraInserm AOA. Simões OliveiraUniversidade do Porto FSF S SaraivaUniversidade do Porto

Key Points

To determine whether simultaneous initiation of ARNi and SGLT2i is noninferior to sequential initiation in patients with HFrEF.
Conducted as a randomized trial.
Participants include patients with heart failure with reduced ejection fraction (HFrEF).
Interventions involve simultaneous versus sequential initiation of ARNi and SGLT2i.
Outcomes assessed include treatment effectiveness and heart failure management efficiency.
The trial aims to show that simultaneous initiation does not lead to worse outcomes than sequential initiation.
Expected findings will clarify optimal treatment strategies for HFrEF.

Abstract

Initiation of ARNi and SGLT2i in Patients With HFrEF is a randomized trial to test whether a simultaneous initiation of ARNi and SGLT2i is noninferior to a sequential initiation of one agent followed by the other 4 to 12 weeks apart.

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Ferreira et al. (Sun,) studied this question.

synapsesocial.com/papers/6988270a0fc35cd7a8845df9 https://doi.org/https://doi.org/10.1016/j.jacadv.2026.102589